Salix starts Xifaxan Phase III

SLXP began a double-blind, placebo-controlled, Mexican Phase III trial of Xifaxan rifaximin to prevent travelers' diarrhea caused by noninvasive strains of E. coli. The primary endpoint of the trial i...